PLRX/ 10/10/2025 · 6:23 AM JPMorgan Downgrades Pliant Therapeutics Amid Strategic Uncertainty JPMorgan cuts Pliant Therapeutics to Underweight rating as the biotech company searches for direction after discontinuing its main drug program earlier this year.